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Imatinib reduces non-alcoholic 
fatty liver disease in obese mice 
by targeting inflammatory and 
lipogenic pathways in macrophages 
and liver
Shefaa AlAsfoor1,2, Theresa V. Rohm1,2, Angela J. T. Bosch1,2, Thomas Dervos1,2, 
Diego Calabrese2, Matthias S. Matter3, Achim Weber4 & Claudia Cavelti-Weder1,2
Macrophages have been recognized as key players in non-alcoholic fatty liver disease (NAFLD). Our aim 
was to assess whether pharmacological attenuation of macrophages can be achieved by imatinib, an 
anti-leukemia drug with known anti-inflammatory and anti-diabetic properties, and how this impacts 
on NAFLD. We analyzed the pro- and anti-inflammatory gene expression of murine macrophages 
and human monocytes in vitro in the presence or absence of imatinib. In a time-resolved study, we 
characterized metabolic disease manifestations such as hepatic steatosis, systemic and adipose 
tissue inflammation as well as lipid and glucose metabolism in obese mice at one and three months of 
imatinib treatment. Our results showed that imatinib lowered pro-inflammatory markers in murine 
macrophages and human monocytes in vitro. In obese mice, imatinib reduced TNFα-gene expression 
in peritoneal and liver macrophages and systemic lipid levels at one month. This was followed by 
decreased hepatic steatosis, systemic and adipose tissue inflammation and increased insulin sensitivity 
after three months. As the transcription factor sterol regulatory element-binding protein (SREBP) links 
lipid metabolism to the innate immune response, we assessed the gene expression of SREBPs and their 
target genes, which was indeed downregulated in the liver and partially in peritoneal macrophages. In 
conclusion, targeting both inflammatory and lipogenic pathways in macrophages and liver as shown by 
imatinib could represent an attractive novel therapeutic strategy for patients with NAFLD.
As a result of the increasing prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) has become one 
of the most common chronic liver diseases worldwide1. NAFLD comprises a wide spectrum of diseases rang-
ing from simple fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which is characterized by infiltra-
tion of immune cells in the liver. In recent years, evidence has accumulated that macrophages play a key role in 
the onset and progression of NAFLD: Liver injury activates resident liver macrophages leading to cytokine and 
chemokine release, which induces the recruitment of bone marrow-derived macrophages (BMDM) into the liver, 
further amplifying the disease process2–4. We use the term “liver macrophages” for both bone marrow-derived 
and resident liver macrophages as their markers strongly overlap5. Targeting liver macrophages has been postu-
lated as a therapeutic strategy for NAFLD3, especially as currently no specific treatment exists. Pharmacological 
macrophage depletion indeed prevents the development of NAFLD in mouse models2,6,7. Similarly, block-
ing bone marrow-derived macrophage recruitment to the liver by pharmacological or genetic ablation of dif-
ferent chemokine or cytokine pathways improves NAFLD characteristics (e.g. CCR2-CCL24,8–10, CCR2/511,12, 
CXCR3-CXCL1013,14, CXCL1615, IL-616, TNFα17). A CCR2/5 antagonist has been tested in a clinical trial with 
promising results regarding fibrosis in NASH patients18. Besides macrophage depletion and blocking macrophage 
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recruitment, pharmacological attenuation of pro-inflammatory macrophages could be an alternative strategy to 
treat NAFLD. As macrophage activation and chronic low-grade inflammation are linked to metabolic disease 
and insulin resistance19, targeting pathologically activated macrophages might even have a broader impact on 
metabolic disease manifestations.
A potential candidate drug with anti-inflammatory properties is the tyrosine kinase inhibitor (TKI) imati-
nib, which was originally developed to target the tumor-associated fusion protein BCR-Abl in chronic myelog-
enous leukemia (CML). Over the years, several other targets of imatinib have been identified20. Most recently, 
imatinib was shown to inhibit posttranslational phosphorylation of PPARγ21, which is an important regula-
tor of macrophage polarization22. Anti-inflammatory effects upon imatinib treatment include adoption of an 
anti-inflammatory phenotype in tumor-associated macrophages23, suppressed glycolysis as an indication for 
anti-inflammatory polarization in leukemia cells24, reduced acute liver injury25, and attenuated adipose tissue 
inflammation in obese mice21. Additionally, glucose-lowering effects have been observed as “side effects” in can-
cer patients treated with imatinib26,27. In diabetic mouse models, these anti-diabetic effects have been attributed to 
reduced β-cell death and maintained β-cell function28–30. The combination of anti-inflammatory and anti-diabetic 
effects is reminiscent of PPARγ-agonists/thiazolidinediones (TZDs), which are anti-diabetic drugs also known 
to dampen macrophage activation31,32. TZDs were even implicated in reduced hepatic steatosis via modulation of 
liver macrophages33. However, due to side effects such as fluid retention, congestive heart failure, weight gain and 
bone fractures, TZDs have been largely abandoned from clinical practice.
Based on the anti-inflammatory and anti-diabetic effects of imatinib potentially involving PPARγ, the aim of 
our study was to assess whether imatinib directly attenuates macrophages and could therefore be used in disease 
states with pathological macrophage activation such as NAFLD. We set out a proof-of-concept study to addresses 
this novel therapeutic concept by testing the effect of imatinib on (1) macrophage activation in vitro, (2) NAFLD 
and other metabolic disease manifestations in a time-resolved manner in vivo, and (3) human monocytes to 
assess its translational application. The concept of pharmacological macrophage attenuation in NAFLD is intrigu-
ing as restoring pathologically activated macrophages could potentially not only target the root cause of NAFLD, 
but also other metabolic disease manifestations such as adipose tissue and systemic inflammation and insulin 
resistance. A more profound understanding of macrophage modulation and the molecular pathways involved 
holds the promise for new treatment strategies in NAFLD and metabolic disease.
Results
Imatinib lowers pro-inflammatory macrophage activation in vitro. Imatinib was tested in differ-
entially activated peritoneal macrophages in vitro (M0, M1, M2) after the optimization of housekeeping genes 
(HKGs), the timing of macrophage activation and the dose of imatinib (Supplementary Fig. S1): In peritoneal 
M1-activated macrophages, imatinib lowered multiple pro-inflammatory genes, most consistently TNFα. 
Accordingly, TNFα and IL-6 protein were lower in the supernatants of imatinib-treated M1-macrophages 
(Fig. 1a). In contrast, pro-inflammatory genes were not altered in unstimulated M0- and anti-inflammatory 
M2-peritoneal macrophages (Fig. 1b). To confirm this immune-dampening effect in a different macrophage 
population, imatinib was tested in BMDM, where it exerted a similar immune-dampening effect, although less 
pronounced than in peritoneal cells (Fig. 1c). To find out whether imatinib only dampens pro-inflammatory 
genes or also promotes anti-inflammatory gene expression, anti-inflammatory genes were similarly assessed 
in differentially activated macrophages. We found higher Mgl1 in M2- and Mrc1 in M1-, but no change in 
M0-macrophages upon imatinib (Fig. 1d). This demonstrates that imatinib primarily lowers pro-inflammatory 
markers in M1-activated macrophages in vitro and does not promote up-regulation of anti-inflammatory genes.
Imatinib lowers peritoneal macrophage activation in acute inflammation and metabolic 
disease models. Next, we asked whether this immune-dampening effect of imatinib on macrophages 
also occurs in vivo. To validate peritoneal macrophages as a direct readout for macrophage attenuation, we 
tested an acute inflammation model by inducing a highly inflammatory response by intraperitoneal (i.p.) 
Lipopolysaccharide (LPS-) injection in mice pretreated with imatinib or water. Imatinib pretreatment lowered 
TNFα gene expression in peritoneal macrophages (Fig. 2a), while anti-inflammatory genes were not altered 
(Supplementary Fig. S2a). To test imatinib in chronic metabolic disease models, diabetic (high fat diet and strep-
tozocin (HFD + STZ)) and obese mice (HFD) were treated with imatinib (IM) or vehicle for up to three months. 
In diabetic mice, TNFα gene expression was significantly lower in peritoneal cells (0.64 ± 0.05 fold) and less 
induced by additional LPS/IFNγ-stimulation when compared to untreated controls (1.8 ± 0.5 and 2.3 ± 0.4 fold, 
respectively, Fig. 2b). Likewise, TNFα gene expression was lower in peritoneal cells of obese mice after one and 
three months of imatinib treatment (both time points 0.58 ± 0.1 fold) and less induced in peritoneal macrophages 
upon additional LPS/IFNγ-stimulation (1.2 ± 0.1 and 2.0 ± 0.3 fold, Fig. 2c). Similar to the acute inflammation 
model, anti-inflammatory genes were not altered (Supplementary Fig. S2b,c). As an additional readout for 
macrophage activation, we used Seahorse analysis, which showed lower metabolic oxidation (OCR) in perito-
neal macrophages from imatinib-treated mice with significantly lower non-mitochondrial and maximum res-
piration (Supplementary Fig. S2d), while only minor effects were found for glycolysis. Thus, imatinib lowers 
pro-inflammatory activation of peritoneal macrophages in acute inflammation and metabolic disease models in 
vivo as assessed by gene expression and metabolic flux.
Imatinib reduces liver macrophages via modulation of the TNFα-pathway. To assess whether 
imatinib also affects liver macrophages, which are key drivers of NAFLD, we performed a time-resolved study 
with HFD-induced obese mice (data summarized in Table 1): Concurrent with TNFα-reduction in peritoneal 
macrophages, imatinib lowered TNFα gene expression in liver tissue after one month. This was followed by a 
reduction in macrophage gene expression after three months of imatinib treatment (Fig. 2e). Co-localization of 
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TNFα and Emr1 (macrophage marker) mRNA in the liver indicated that TNFα-reduction occurred in liver mac-
rophages (Fig. 2d). Consistent with gene expression, F4/80 area fraction showed no change after one month, but 
prevention of the HFD-induced increase in liver macrophages after three months of imatinib treatment (Fig. 2f,g). 
The immune-modulation was specific to macrophages, as other immune cells such as B- and T-lymphocytes and 
neutrophils were not affected in the liver (Fig. 2h,i). Thus, imatinib leads to early TNFα-reduction in liver mac-
rophages, which later prevents the HFD-induced increase in liver macrophages.
Early TNFα-reduction in macrophages is accompanied by changes in lipid metabolism, fol-
lowed later by markedly decreased hepatic steatosis. We used our time-resolved approach to 
address the question whether and in what time frame liver macrophage attenuation by imatinib impacts on liver 
Figure 1. Imatinib lowers pro-inflammatory macrophage activation in vitro. (a) Fold change gene expression 
of pro-inflammatory markers in M1-peritoneal macrophages treated with 1 μM of imatinib (M1 + IM, open 
bars) compared to non-treated M1-controls (M1, closed bar) (n = 8–26). Fold change of TNFα and IL-6 
protein in the supernatant of unstimulated (M0), activated (M1) and concomitantly activated/imatinib-treated 
(M1 + IM) peritoneal macrophages (n = 4–13). (b) Fold change of pro-inflammatory gene expression in 
unstimulated/imatinib-treated (M0 + IM, n = 12–18) and anti-inflammatory/imatinib-treated macrophages 
(M2 + IM, n = 3–12) compared to their respective controls (M0 or M2). (c) Fold change of pro-inflammatory 
gene expression in activated/imatinib-treated BMDM (M1 + IM) and controls (M1) (n = 8–13). Fold change 
of TNFα and IL-6 protein in the supernatant of unstimulated (M0), activated (M1) and concomitantly 
activated/imatinib-treated (M1 + IM) BMDM (n = 6–13). Gene expression of anti-inflammatory genes in 
BMDM (n = 6–9) treated with imatinib compared to non-treated M1-controls. (d) Gene expression of anti-
inflammatory genes in M1-activated (n = 6–9), unstimulated M0 (n = 12–18) and anti-inflammatory M2-
peritoneal macrophages (n = 6–12) treated with imatinib compared to their respective controls (M1, M0, M2). 
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. Imatinib lowers pro-inflammatory activation in peritoneal and liver macrophages in vivo. (a) Fold 
change of pro-inflammatory genes in peritoneal macrophages in the acute inflammation model (LPS + IM: 
imatinib pretreated mice; LPS: water treated controls; n = 4–6). (b) Fold change of pro-inflammatory genes in 
peritoneal cells and in peritoneal macrophages upon ex vivo stimulation with LPS/IFNγ from diabetic mice 
treated for one month with imatinib (HFD + STZ + IM) compared to water-treated controls (HFD + STZ) 
(n = 3–6). (c) Fold change of pro-inflammatory genes in peritoneal cells and in peritoneal macrophages upon 
ex vivo LPS/IFNγ-stimulation from obese mice (HFD + IM) treated with imatinib compared with water-treated 
controls (HFD) (n = 4–10). (d) In situ hybridization for TNFα (red) and Emr1 (green) mRNA and DAPI 
nuclear staining (blue) in liver sections from chow, HFD and HFD + IM-treated mice. (e) Fold change gene 
expression of macrophage markers CD68 and Emr1 and TNFα in HFD + IM-treated mice compared to HFD 
controls after one and three months of imatinib (n = 5–7). (f,g) Representative liver sections stained for F4/80 
from chow, HFD-fed and HFD + IM-treated mice and quantification by macrophage area fraction (%) at one 
and three months of imatinib treatment. (h,i) Representative liver sections stained for B220, CD3, Ly-6G and 
DAPI from chow, HFD-fed and HFD + IM-treated mice and quantification by % of cells/ DAPI + parenchymal 
cells at three months of imatinib. HFD: High fat diet, IM: imatinib, mos: months, PC: peritoneal cells, PM: 
peritoneal macrophages. Scale bar represents 100μm. Data expressed as mean ± SEM, *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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outcomes: Besides TNFα-reduction in the liver, the earliest change we observed were lowered systemic lipid 
levels after one month of imatinib treatment, also persisting at three months (Fig. 3a,b). All other tissue changes 
were only observed after three months of imatinib treatment (Table 1): The stark increase in hepatic steatosis in 
mice on HFD compared to chow was almost completely resolved after three months of imatinib treatment as 
histologically quantified by the NAFLD activity score (NAS-)score (Fig. 3c,d; Supplementary Fig. S3). Fibrosis 
was not induced by our obesity model and therefore did not affect the NAS-score. These morphological changes 
also affected liver function as shown by lower alkaline phosphatase after three months of imatinib (Fig. 3e). 
Additionally, three months of imatinib prevented the HFD-induced increase in plasma TNFα-levels (Fig. 3f). 
Thus, besides TNFα-reduction in the liver imatinib leads to early changes in lipid metabolism, which is later 
followed by markedly decreased hepatic steatosis.
Imatinib lowers adipose tissue inflammation and increases insulin sensitivity after three 
months. We also studied the effect of imatinib on other metabolic disease manifestations such as adipose 
tissue inflammation and glucose metabolism in a time-resolved manner (Table 1): While there was no change 
in adipose tissue inflammation after one month of imatinib, the HFD-induced increase in macrophages and 
pro-inflammatory markers in adipose tissue was reversed by three months of imatinib treatment (Fig. 4a). Flow 
cytometry confirmed a higher frequency of macrophages in the adipose tissue of HFD-fed animals compared 
to mice treated for 3 months with imatinib. However, absolute numbers of adipose tissue subpopulations were 
unchanged (Supplementary Fig. S4). In terms of glucose metabolism, diabetic mice had slightly increased insu-
lin sensitivity after one month of imatinib when compared to vehicle-treated mice, while glucose tolerance was 
unaltered (Fig. 4b). After one month of treatment, obese mice showed no change in body weight or glucose and 
insulin tolerance. However, after three months a comparable pattern as in the diabetic model was observed with 
increased insulin sensitivity, yet unchanged glucose tolerance (Fig. 4c). Taken together, reduced adipose tissue 
inflammation and increased insulin sensitivity occur after up to three months of imatinib treatment.
Time-resolved assessment of transcription factors suggests that imatinib targets SREBP, while 
restoration of PPARγ-phosphorylation is a secondary phenomenon. As the transcription factor 
sterol regulatory element-binding protein (SREBP) links lipid metabolism to the innate immune response34 that 
were both early affected with imatinib treatment, we assessed the target genes of the three isoforms SREBP1a, 
SREBP1c and SREBP2: Imatinib downregulated SREBP1c gene expression in cultures of peritoneal macrophages, 
which was corroborated in vivo after one month of imatinib treatment (Fig. 5a,b). SREBP1a and its target genes 
1 month IM 3 months IM
Peritoneal cells
TNFα gene expression 0.58 ± 0.1 0.58 ± 0.1
SREBP1c target genes 1/4 reduced 0/4 reduced
pS273 PPARγ-related genes 0/12 induced 1/12 induced
Liver
TNFα gene expression 0.48 ± 0.1 0.41 ± 0.1
SREBP1a target genes 1/3 reduced
SREBP1c target genes 3/8 reduced 1/8 reduced
SREBP2 target genes 2/6 reduced 1/6 reduced
CD68 gene expression 0.95 ± 0.1 0.50 ± 0.1
F4/80 gene expression 1.0 ± 0.1 0.71 ± 0.1 (trend)
F4/80 area fraction 0.86 ± 0.1 0.38 ± 0.1
NAS-score 0.9 ± 0.2 0.42 ± 0.2
Alkaline phosphatase not detected 0.59 ± 0.1
Systemic
Cholesterol 0.75 ± 0.05 0.7 ± 0.1
HDL 0.77 ± 0.05 0.76 ± 0.1
Triglycerides 1.05 ± 0.1 0.8 ± 0.1
TNFα 0.9 ± 0.05 0.43 ± 0.1
Adipose tissue
TNFα gene expression 0.55 ± 0.2 0.39 ± 0.1
CD68 gene expression 0.93 ± 0.2 0.57 ± 0.2
F4/80 gene expression 0.88 ± 0.1 0.48 ± 0.1
pS273 PPARγ-related genes 0/17 induced 5/17 induced
Metabolic tests
ITT ns s
GTT ns ns
Table 1. Summary time resolved study (1 and 3 months imatinib) in obese mice. Statistical differences between 
one and three months data are indicated in bold font. Data presented as mean ± SEM.
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Nlrp1a and Nlrp1c, in contrast, were not altered in peritoneal cells. In the liver, 3/8 SREBP1c and 2/6 SREBP2 
target genes were significantly downregulated after one month imatinib (Fig. 5d). Interestingly, after three months 
of imatinib treatment, SREBP target gene expression was mostly normalized to baseline in both peritoneal cells 
and liver tissue (Fig. 5c,e), suggesting that compensatory mechanisms might occur over time.
Another transcription factor that has been shown to control both inflammatory responses and lipid metab-
olism is PPARγ35. In the context of metabolic disease, PPARγ has been shown to become phosphorylated at 
serine273, leading to dysregulation of a large number of metabolically important genes36. Imatinib was shown 
to inhibit PPARγ-phosphorylation at serine273, thereby reducing insulin resistance and promoting browning 
Figure 3. Early TNFα-reduction in macrophages is accompanied by changes in lipid metabolism, followed 
later by markedly decreased hepatic steatosis. (a,b) Plasma cholesterol, triglycerides and High-density 
lipoprotein (HDL) in chow, HFD and HFD + IM-treated mice after one (a) and three months of imatinib 
treatment (b; n = 4–7). (c) Representative H&E liver stainings from chow, HFD-fed and HFD + IM-treated 
mice. (d) Quantification of NAFLD features by the NAS-score in chow, HFD and HFD + IM-treated mice. (e) 
Alkaline phosphatase (AP) in chow, HFD and HFD + IM-treated mice (n = 4–7). (f) Fold change of systemic 
TNFα protein in chow, HFD and HFD + IM-treated mice (n = 5–7). HFD: High fat diet, IM: imatinib, mos: 
months. Scale bar represents 100 μm. Data expressed as mean ± SEM, *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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of white adipose tissue21. We therefore assessed genes related to PPARγ-phosphorylation at serine273 in our 
time-resolved study. In white adipose tissue, PPARγ-phosphorylation-related genes were dysregulated (low-
ered) by HFD mainly at the three months’ time point (Supplementary Fig. S5a) when also restoration of these 
genes occurred by imatinib (upregulation of 5/17 PPARγ-phosphorylation-related genes; Fig. 5f). In peritoneal 
cells, no changes in PPARγ-phosphorylation-related genes were found at both one and three months of imatinib 
(Supplementary Fig. S5b), suggesting that phosphorylation at serine273 (pS273) is not directly affected in mac-
rophages. Thus, the early immune-dampening effect in macrophages precedes restored PPARγ-phosphorylation 
in adipose tissue, indicating that restoration of PPARγ-phosphorylation-related genes might be a secondary 
phenomenon.
As a last potential mechanism, we assessed genes involved in thermogenesis as imatinib has previously been 
shown to induce browning of adipose tissue21. However, we did not find upregulation of cold-induced thermo-
genesis genes Pcg1α, Ucp-1, Cox5b, Cpt1b and Dio2 in inguinal adipose tissue of HFD-fed mice upon imatinib 
treatment (Supplementary Fig. S5c). In sum, our time-resolved assessment of potential pathways suggests that 
SREBP-signaling is affected in liver and partially in macrophages, while restoration of PPARγ-phosphorylation at 
pS273 seems to be a secondary phenomenon upon imatinib.
Imatinib lowers pro-inflammatory activation in human monocytes, but hyperglycemia alters 
their responsiveness. Finally, we assessed whether immune-modulation by imatinib could also be achieved 
in human monocytes. As hyperglycemia is known to impact on monocyte activation37 and our in vitro data 
showed a differential response to imatinib depending on the activation state, we tested the effect of imatinib 
on monocytes from subjects with markedly distinct glycemia, including healthy controls (He), diabetics with 
Figure 4. Imatinib reduces adipose tissue inflammation and increases insulin sensitivity over time. (a) Fold 
change gene expression of macrophage markers (CD68, F4/80) and pro-inflammatory M1-markers (TNFα, 
IL-6) in whole adipose tissue of chow, HFD and HFD + IM-treated animals (n = 5–7). (b) Body weight, 
insulin sensitivity and glucose tolerance with insulin in diabetic mice treated for one month with imatinib 
(HFD + STZ + IM) and controls (HFD + STZ; n = 4–5). (c) Body weight, insulin sensitivity and glucose 
tolerance with insulin in obese mice treated for three months with imatinib (HFD + IM) and controls (HFD; 
n = 5–6). HFD: High fat diet, IM: imatinib, mos: months, SAC: sacrifice, STZ: Streptozocin. Data expressed as 
mean ± SEM, *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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adequate (aDM) or inadequate glycemic control (iaDM). Supplementary Table S4 shows the baseline charac-
teristics with the intended main differences between aDM and iaDM patients concerning their glycemic con-
trol (HbA1c aDM 52.6 ± 5.5 mmol/mol (7.0 ± 0.5%), iaDM 114.5 ± 6.5 mmol/mol (12.6 ± 0.6%)). Imatinib 
lowered the pro-inflammatory markers TNFα, MCP-1 and CD163 in unstimulated monocytes of all groups, 
while this immune-dampening effect was gradually lost in M1-activated monocytes with deranged glycemic 
control (Fig. 6a,b). Increasing the dose of imatinib did not restore the immune-dampening effect in iaDM 
patients (Fig. 6c). In sum, unstimulated human monocytes respond to imatinib treatment by down-regulation of 
pro-inflammatory markers. However with deranged glycemic control, the immune-dampening effect of imatinib 
is lost in activated monocytes, suggesting altered susceptibility to the drug with hyperglycemia.
Discussion
When first testing the notion of an immune-dampening effect of imatinib on macrophages in vitro, we found 
lower pro-inflammatory gene and protein expression, most consistently TNFα, while anti-inflammatory genes 
were not upregulated. This was slightly less pronounced in BMDM, most likely due to the artificial differenti-
ation by exogenous Macrophage colony-stimulating factor (M-CSF) over one week. To translate our findings 
in vivo, we performed a time-resolved study assessing the effects of imatinib on macrophages and metabolic 
disease manifestations in HFD-induced obese mice: Reduction of TNFα in peritoneal and liver macrophages 
occurred most rapidly upon imatinib. Activated peritoneal macrophages are known to have both enhanced gly-
colysis and mitochondrial oxidation38. Metabolic flux as another measure for macrophage activation confirmed 
altered polarization by lower metabolic oxidation upon imatinib. In the liver, we were able to localize TNFα in 
liver macrophages, which decreased over time as shown by lower F4/80 area fraction and CD68 gene expression. 
Figure 5. SREBP target genes are downregulated upon imatinib treatment, while PPARγ-phosphorylation 
seems to be a secondary phenomenon. (a) Fold change gene expression of SREBP target genes in M1-
stimulated peritoneal macrophages treated with or without imatinib (IM) in vitro (n = 9). (b,c) Fold change 
gene expression of SREBP target genes in peritoneal cells after one and three months of imatinib treatment 
(n = 4–7). (d,e) Fold change gene expression of SREBP target genes in whole liver tissue after one and three 
months of imatinib (n = 5–9). (f) Fold change gene expression of PPARγ-phosphorylation-regulated genes 
in obese mice treated with imatinib (HFD + IM) compared with water-treated controls (HFD) after one (left) 
and three months of imatinib treatment (right; n = 5–10). AT: adipose tissue, HFD: High fat diet, IM: imatinib, 
mos: months, PC: peritoneal cells, PM: peritoneal macrophages. Data expressed as mean ± SEM, *p < 0.05, 
**p < 0.01, ***p < 0.001.
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Thus, it is conceivable that down-regulation of TNFα by imatinib interrupts the vicious cycle of resident liver 
macrophage activation and/or bone marrow-derived macrophage recruitment to the liver, subsequently lowering 
their activation and/or number.
Concomitant with early TNFα-reduction in macrophages, imatinib led to lipid lowering effects, indicative 
for a mechanism that integrates both innate immunity and lipid metabolism. To assess a common mechanism 
involving both inflammation and lipogenesis, we first focused on the SREBP transcription factor family, which 
is known to activate lipogenic transcriptional programs, but has also been shown to control transcriptional reg-
ulation that extends beyond lipid synthesis39: For example, SREBP1a is highly expressed in immune cells such as 
macrophages and dendritic cells, where it not only activates genes required for lipogenesis but also a gene encod-
ing Nlrp1, a core component of the inflammasome34. Thus, SREBP links lipid metabolism and the innate immune 
response and could therefore explain the simultaneous effects on inflammation and lipid levels we observed upon 
imatinib treatment. We found early reductions of SREBP1c-target genes in the liver and partially in peritoneal 
macrophages. These downregulations were gone after three months of imatinib treatment, most likely due to com-
pensatory mechanisms. We speculate that the SREBP transcriptional program of the target cell determines the 
phenotypic alteration induced by imatinib: In macrophages, imatinib has preferentially an immune-dampening 
Figure 6. Imatinib lowers pro-inflammatory activation in human monocytes, but hyperglycemia alters their 
responsiveness. (a,b) Fold change gene expression of TNFα, MCP-1 and CD163 in human M0- (a) or M1-
monocytes (b) treated with 1 μM of imatinib (M0 + IM or M1 + IM, open bars) compared to non-treated M0- 
or M1-monocytes (M0 or M1, closed bar) from healthy controls (He, n = 6), adequately controlled diabetics 
(aDM, n = 5) and inadequately controlled diabetics (iaDM, n = 5). (c) Fold change of gene expression of TNFα, 
MCP-1 and CD163 with increasing doses of imatinib (1, 2.5, 5 μM) in inadequately controlled diabetics (n = 3). 
Data expressed as mean ± SEM, *p < 0.05, **p < 0.01.
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effect, while in the liver also lipogenesis is affected. Thus, improvements in metabolic disease manifestations likely 
arise from a combination of the immune-dampening effect on macrophages and lowered lipogenesis induced 
by imatinib. Hence, in the long-term, lower SREBP target gene expression upon imatinib was associated with 
reduced hepatic steatosis, systemic and adipose tissue inflammation and increased insulin sensitivity.
Another transcription factor involved in both inflammation and lipid metabolism is PPARγ35. In obesity 
and insulin resistance, PPARγ was shown to become phosphorylated at serine273 with subsequent dysreg-
ulation of metabolically important genes36. Interestingly, PPARγ-phosphorylation at serine273 was blocked 
by imatinib, thereby restoring dysregulated diabetes-genes and reducing insulin resistance21. However, in our 
time-resolved assessment the early immune-dampening effect on macrophages and reduction in lipid levels 
clearly preceded restoration of PPARγ-phosphorylation-related genes in adipose tissue, indicating that restored 
PPARγ-phosphorylation might be a secondary phenomenon. Restoration of PPARγ-phosphorylation-related 
genes in adipose tissue potentially develops as less TNFα is available to engage in PPARγ-phosphorylation and 
its deleterious metabolic downstream effects. A recent study demonstrated that imatinib interferes with the inter-
action between the histone H3 lysine 4 methyltransferase MLL4 and PPARγ, thereby dampening steatotic target 
genes in short-term experiments40. Thus, dampened SREBP transcriptional programs as observed in our study 
could ultimately be due to imatinib interfering with the MLL4-PPARγ axis with subsequently reduced transcrip-
tion of SREBP target genes.
As a third potential mechanistic pathway, we assessed browning of adipose tissue by imatinib, however, we 
were not able to find consistent upregulation of cold-induced thermogenesis genes. This is in contrast to the pub-
lication by Choi and colleagues21, which could be explained by differences in the study set-up (administration of 
imatinib i.p. versus oral; treatment duration and genetic background (C57BL/6 J versus C57BL/6 N)). The latter is 
insofar important as genetic variability is known to affect cold-induced thermogenesis41.
To translate our findings to human disease, we probed the effect of imatinib on human monocytes. Especially, 
as previous studies showed a heightened inflammatory state in human myeloid cells with hyperglycemia37,42, 
diabetic patients could exhibit altered susceptibility to immune-modulatory drugs like imatinib. Human mono-
cytes responded to imatinib treatment by down-regulation of pro-inflammatory markers also in a non-activated 
state. This is consistent with previous studies showing that monocytes have a “pre-activated” basal condition that 
requires only a single stimulation, while macrophages depend on a second signal to be activated43. In activated 
monocytes, however, the immune-dampening effect of imatinib was lost with deranged glycemic control, sug-
gesting altered susceptibility to the drug with hyperglycemia, and could not be overcome with increasing doses of 
imatinib. Although the extreme stimulation as achieved by ex vivo LPS/IFNγ-stimulation might not represent the 
in vivo situation, it uncovers altered susceptibility to immune-modulation with hyperglycemia.
The strength of our study is that the long-term follow-up and time-resolved approach allowed us to distin-
guish early from later effects of imatinib on different cells and organs. Hence, it became clear that imatinib simul-
taneously affects inflammatory and lipogenic signals in macrophages and in the liver before reducing metabolic 
disease manifestations such as NAFLD, systemic and adipose tissue inflammation or insulin resistance. Our find-
ings expand on previous literature by linking SREBP-signaling not only to lipogenesis, but also to innate immu-
nity in the context of NAFLD. A more profound understanding of integrated pathways between inflammation 
and lipid metabolism could pave the way for the development of novel therapeutics in NAFLD.
The clinical significance of our findings lies in the scarcity of therapeutic measures available for NAFLD 
patients. Imatinib has generally a mild adverse effect profile and long-term safety record. In rare instances, how-
ever, imatinib has been associated with acute liver injury often in connection with hepatotoxic agents interfering 
with cytochrome P450 enzymes, leading to increased imatinib concentrations44. Thus, taking this into account, 
clinical trials could be envisaged in the context of NAFLD. Imatinib has already been tested in the setting of type 
1 diabetes mellitus, however, the results have not yet been published45. In the light of our findings that imatinib 
exerts effects both on innate immunity and lipid metabolism, clinical studies involving patients with metabolic 
disease – preferentially with chronic low-grade inflammation and NAFLD – could yield promising results in the 
future.
Materials and Methods
Animals. Male C57BL/6 N mice (Charles River Laboratories, Sulzfeld, Germany) were maintained in our SPF-
facility at 22 °C room temperature with 12 h light/12 h dark cycle and were housed in groups of 3–5 mice. Body 
weights were monitored once weekly. Mice used for metabolic experiments were kept for 1 week of acclimation 
period upon arrival. All procedures were approved by the local Animal Care and Use Committee (Veterinary 
Office Basel, Switzerland) and carried out in accordance with relevant guidelines and regulations.
Murine macrophages. Peritoneal cells were harvested from 6–8-week old male C57BL/6 N mice by 
intra-abdominal lavage, cultured overnight and enriched for macrophages by washing away non-adherent peri-
toneal cells. For BMDM, bone marrow cells were isolated from murine femur and tibia and differentiated by 
M-CSF (10 ng/mL, PeproTech, London, UK) for 7–9 days. Peritoneal macrophages or BMDM were polarized to 
a pro- (M1; 10 ng/mL IFNγ, PeproTech, 100 ng/mL LPS E. coli 0111:B4, Sigma-Aldrich, Saint Louis, MO, USA) 
or anti-inflammatory phenotype (M2; 10 ng/mL IL-4 and IL-13, Thermo Fisher Scientific, Waltham, MA, USA) 
or left unstimulated (M0) in the presence or absence of imatinib (1 μM, Novartis, Basel, Switzerland) for 6 hours.
Gene expression analysis. RNA was isolated using NucleoSpin RNA kit (Macherey Nagel, Düren, 
Germany) and RNeasy Plus Universal Mini kit (QIAGEN, Düsseldorf, Germany). Reverse transcription was 
performed with SuperScriptII Reverse Transcriptase kit (Thermo Fisher Scientific). GoTaq qPCR Master Mix 
(Promega, Madison, WI, USA) was used for real-time PCR (ViiA7, Thermo Fisher Scientific). Primer sequences 
(Microsynth, Balgach, Switzerland) are listed in Supplementary Table S1.
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Protein expression analysis. Plasma insulin, TNF-α and IL-6 were quantified by electrochemilumines-
cence (MESO SECTOR S 600) using kits from MesoScale Diagnostics (MSD, Rockville, MD, USA).
Acute in vivo inflammation model. Imatinib (100 mg/kg) or water was administered by gavage three 
times during 24 h prior to a single i.p. LPS-injection (1 mg/kg). Analysis was performed 2 h post LPS and perito-
neal cells and macrophages assessed by PCR.
Chronic in vivo inflammation model. Mice on high fat diet (HFD containing 58% fat, 16.4% protein and 
25.6% carbohydrate, Research diet, New Brunswick, NJ, USA; start at 4–5 weeks of age for 14–27 weeks) and mice 
on HFD with a single i.p. injection of streptozocin (at week three of HFD STZ 130 mg/kg, Sigma-Aldrich) were 
treated with oral imatinib (gavage 100 mg/kg) or water for one or three months. A dose of 100 mg/kg imatinib has 
been reported to reach slightly lower steady state plasma concentrations (1 μM at 8 hours46) compared to humans 
treated with 400 mg imatinib daily (1.46 μM at 24 hours47) due to faster clearance in mice. Insulin and glucose tol-
erance tests (ITT/ GTT) were performed at 4 or 8 weeks of imatinib treatment with blood samplings from the tail 
vein before and 15, 30, 60 and 90 minutes after i.p. injection of 2 g/kg body weight glucose or 2U/kg body weight 
insulin. Peritoneal cells and macrophages were harvested as described for in vitro experiments. Other readout 
measures are specified below.
Seahorse XF flux analysis. Glycolysis (ECAR; extracellular acidification rate) and mitochondrial res-
piration (OCR, oxygen consumption rate) were measured by XF96 Seahorse Metabolic Analyzer (Seahorse 
Bioscience, North Billerica, MA, USA) in peritoneal macrophages ex vivo as previously described48.
Flow cytometry of adipose tissue macrophages. Epididymal adipose tissue was minced and digested 
using collagenase IV (Worthington, OH, USA) and DNAse I (Sigma-Aldrich) at 37 °C for 25–30 min. To identify 
adipose tissue macrophages (ATMs), cells were stained with specific surface markers (Supplementary Table S2) 
and analyzed using the BD LSRII instrument (BD Biosciences, Franklin Lakes, NJ, USA) and FlowJo software 
(TreeStar Inc., Ashland, OR, USA). Among single (Singlets), live (DAPI−) leukocytes (CD45+) and after excluding 
eosinophils (CD45+F4/80lowSiglecF+) ATMs (non-eosinophils CD11b+F4/80+) were classified as double negative 
(DN), monocyte-derived M1a (CD11c+CD206−), inflammatory M1b (CD11c+CD206mid) and anti-inflammatory 
M2 (CD11c− to lowCD206high) (gating strategy: Supplementary Fig. S4a–c).
Liver histology. Hematoxylin-eosin (H&E) was performed according to established protocols and the 
NAS-score49 assessed in a blinded fashion. Immunohistochemistry (IHC) for F4/80, CD3, B220, and Ly-6G (anti-
bodies in Supplementary Table S3) was performed on paraffin-embedded liver sections. For quantification of 
immune cells, liver sections were scanned by a Prior robot/Nikon slide scanner. Three independent visual fields 
were semi-automatically quantified for area fraction (F4/80) or number of cells per DAPI-positive parenchymal 
cells (CD3, B220, Ly-6G) using the Nikon software (NIS) tool.
In situ hybridization (ISH). Mouse TNFα (VB1-10175-VT) and Emr1 (VB6-12917-VT) genes were 
detected in formalin fixed, paraffin embedded (FFPE), 5μm liver sections using the ViewRNA ISH system 
(Affymetrix, Santa Clara, CA, USA) as previously described50. Brightfield and fluorescent images were acquired 
using a laser scanning confocal microscope (LSM710, Zeiss, Oberkochen, Germany) and Zen2 software (Zeiss) 
and subjected to image processing with ImageJ software.
Liver enzymes and lipids. Liver enzymes and blood lipids were measured in mouse plasma using a Cobas 
8000 modular analyzer (Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s protocol.
Human monocytes. Study approval was obtained from the local ethics committee (Ethics Committee of 
northwest and central Switzerland, EKNZ). The human study was conducted in accordance with the Declaration 
of Helsinki and relevant guidelines and regulations. All diabetic subjects (HbA1c > 6.5%) and healthy volun-
teers (BMI 18–25 kg/m2) gave written, informed consent. Detailed medical history and baseline characteristics 
were obtained at the day of the blood draw. Monocytes were enriched using MagniSort® Human Pan-Monocyte 
Enrichment kit (Thermo Fisher Scientific) from peripheral blood mononuclear cells (PBMCs). Human mono-
cytes were kept for 2 h to attach and then activated towards a pro-inflammatory phenotype (M1; 10 ng/mL IFNγ, 
ImmunoTools, Friesoythe, Germany, 100 ng/mL Lipopolysaccharide (LPS) E. coli 0111:B4, Sigma-Aldrich, Saint 
Louis, MO, USA) or left unstimulated (M0) in the presence or absence of imatinib (1 μM) for 24 h.
Data analysis. Data are expressed as mean ± SEM. Unpaired Mann-Whitney test was used for statistical 
significance (GraphPad Prism). A p-value < 0.05 was considered as statistically significant.
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